Simon Y Graeber1,2,3,4, Christian Dopfer5,6, Lutz Naehrlich7,8, Lena Gyulumyan5, Heike Scheuermann1, Stephanie Hirtz1, Sabine Wege9, Heimo Mairbäurl3,9,10, Marie Dorda5,6, Rebecca Hyde5,6, Azadeh Bagheri-Hanson7, Claudia Rueckes-Nilges7,8, Sebastian Fischer5,6, Marcus A Mall1,2,3,4, Burkhard Tümmler5,6. 1. 1 Department of Translational Pulmonology. 2. 2 Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center, Department of Pediatrics, and. 3. 3 Translational Lung Research Center Heidelberg, German Center for Lung Research, University of Heidelberg, Heidelberg, Germany. 4. 4 Department of Pediatric Pulmonology and Immunology and Cystic Fibrosis Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. 5. 5 Clinic of Pediatric Pneumology, Allergology, and Neonatology and. 6. 6 Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover Medical School, Hannover, Germany. 7. 7 Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany. 8. 8 Universities of Giessen and Marburg Lung Center, German Center for Lung Research, Giessen, Germany. 9. 9 Department of Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany; and. 10. 10 Medical Clinic VII, Sports Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Abstract
RATIONALE: The combination of the CFTR (cystic fibrosis transmembrane conductance regulator) corrector lumacaftor with the potentiator ivacaftor has been approved for the treatment of patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. The phase 3 trials examined clinical outcomes but did not evaluate CFTR function in patients. OBJECTIVES: To examine the effect of lumacaftor-ivacaftor on biomarkers of CFTR function in Phe508del homozygous patients with cystic fibrosis aged 12 years and older. METHODS: This prospective observational study assessed clinical outcomes including FEV1% predicted and body mass index, and CFTR biomarkers including sweat chloride concentration, nasal potential difference, and intestinal current measurement before and 8-16 weeks after initiation of lumacaftor-ivacaftor. MEASUREMENTS AND MAIN RESULTS: A total of 53 patients were enrolled in the study, and 52 patients had baseline and follow-up measurements. After initiation of lumacaftor-ivacaftor sweat chloride concentrations were reduced by 17.8 mmol/L (interquartile range [IQR], -25.9 to -6.1; P < 0.001), nasal potential difference showed partial rescue of CFTR function in nasal epithelia to a level of 10.2% (IQR, 0.0-26.1; P < 0.011), and intestinal current measurement showed functional improvement in rectal epithelia to a level of 17.7% of normal (IQR, 10.8-29.0; P < 0.001). All patients improved in at least one CFTR biomarker, but no correlations were found between CFTR biomarker responses and clinical outcomes. CONCLUSIONS: Lumacaftor-ivacaftor results in partial rescue of Phe508del CFTR function to levels comparable to the lower range of CFTR activity found in patients with residual function mutations. Functional improvement was detected even in the absence of short-term improvement of FEV1% predicted and body mass index. Clinical trial registered with www.clinicaltrials.gov (NCT02807415).
RATIONALE: The combination of the CFTR (cystic fibrosis transmembrane conductance regulator) corrector lumacaftor with the potentiator ivacaftor has been approved for the treatment of patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. The phase 3 trials examined clinical outcomes but did not evaluate CFTR function in patients. OBJECTIVES: To examine the effect of lumacaftor-ivacaftor on biomarkers of CFTR function in Phe508del homozygous patients with cystic fibrosis aged 12 years and older. METHODS: This prospective observational study assessed clinical outcomes including FEV1% predicted and body mass index, and CFTR biomarkers including sweat chloride concentration, nasal potential difference, and intestinal current measurement before and 8-16 weeks after initiation of lumacaftor-ivacaftor. MEASUREMENTS AND MAIN RESULTS: A total of 53 patients were enrolled in the study, and 52 patients had baseline and follow-up measurements. After initiation of lumacaftor-ivacaftor sweat chloride concentrations were reduced by 17.8 mmol/L (interquartile range [IQR], -25.9 to -6.1; P < 0.001), nasal potential difference showed partial rescue of CFTR function in nasal epithelia to a level of 10.2% (IQR, 0.0-26.1; P < 0.011), and intestinal current measurement showed functional improvement in rectal epithelia to a level of 17.7% of normal (IQR, 10.8-29.0; P < 0.001). All patients improved in at least one CFTR biomarker, but no correlations were found between CFTR biomarker responses and clinical outcomes. CONCLUSIONS:Lumacaftor-ivacaftor results in partial rescue of Phe508del CFTR function to levels comparable to the lower range of CFTR activity found in patients with residual function mutations. Functional improvement was detected even in the absence of short-term improvement of FEV1% predicted and body mass index. Clinical trial registered with www.clinicaltrials.gov (NCT02807415).
Entities:
Keywords:
cystic fibrosis; cystic fibrosis transmembrane conductance regulator biomarker; intestinal current measurement; nasal potential difference; sweat test
Authors: Luis Torres; Jeff Kammerman; Andrew D Hahn; Wei Zha; Scott K Nagle; Kevin Johnson; Nathan Sandbo; Keith Meyer; Mark Schiebler; Sean B Fain Journal: Acad Radiol Date: 2019-01-16 Impact factor: 3.173
Authors: Sangwoo T Han; Andras Rab; Matthew J Pellicore; Emily F Davis; Allison F McCague; Taylor A Evans; Anya T Joynt; Zhongzhou Lu; Zhiwei Cai; Karen S Raraigh; Jeong S Hong; David N Sheppard; Eric J Sorscher; Garry R Cutting Journal: JCI Insight Date: 2018-07-26
Authors: John Paul Clancy; Calvin U Cotton; Scott H Donaldson; George M Solomon; Donald R VanDevanter; Michael P Boyle; Martina Gentzsch; Jerry A Nick; Beate Illek; John C Wallenburg; Eric J Sorscher; Margarida D Amaral; Jeffrey M Beekman; Anjaparavanda P Naren; Robert J Bridges; Philip J Thomas; Garry Cutting; Steven Rowe; Anthony G Durmowicz; Martin Mense; Kris D Boeck; William Skach; Christopher Penland; Elizabeth Joseloff; Hermann Bihler; John Mahoney; Drucy Borowitz; Katherine L Tuggle Journal: J Cyst Fibros Date: 2018-06-20 Impact factor: 5.482
Authors: Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen Journal: Lancet Respir Med Date: 2019-09-27 Impact factor: 30.700
Authors: Scott H Donaldson; Beth L Laube; Peter Mogayzel; Timothy E Corcoran; Joseph M Pilewski; Agathe Ceppe; Jihong Wu; Pradeep G Bhambhvani; Felix Ratjen; Scott D Sagel; J P Clancy; Steven M Rowe; William D Bennett Journal: J Cyst Fibros Date: 2021-05-31 Impact factor: 5.482
Authors: Matthew S McCravy; Nancy L Quinney; Deborah M Cholon; Susan E Boyles; Timothy J Jensen; Andrei A Aleksandrov; Scott H Donaldson; Peadar G Noone; Martina Gentzsch Journal: Eur Respir J Date: 2020-07-30 Impact factor: 16.671